SUMMARY
INTRODUCTION

Th17 cells, CD4
+ T cells that secrete interleukin-17 (IL-17), play a critical role in inflammatory pathology in organ-specific autoimmune diseases, including multiple sclerosis (MS) and rheumatoid arthritis, a role hitherto attributed to Th1 cells (Harrington et al., 2005; Koenders et al., 2005; Langrish et al., 2005; Park et al., 2005) . Furthermore, Th17 cells play a role in immunity to infection, for which they are generated through induction of innate cytokines via activation of Toll-like receptors (TLRs) and NOD-like receptors (NLRs) (Higgins et al., 2006; Veldhoen et al., 2006) . IL-6 and transforming growth factor (TGF)-b can induce the differentiation of naive murine T cells into Th17 cells (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006) . IL-21 is also a key cytokine in the differentiation of murine and human CD4 IL-23p19-deficient (Il23a À/À ) mice are resistant to the induction of experimental autoimmune encephalomyelitis (EAE) (Cua et al., 2003) , and IL-23 was initially thought to be the critical cytokine in the differentiation of Th17 cells. However, naive murine T cells do not express IL-23R and do not differentiate into Th17 cells in response to IL-23 in vitro (Langrish et al., 2005; van Beelen et al., 2007) . In contrast, IL-23 can expand Th17 cells from memory CD4 + T cells (Aggarwal et al., 2003) . We have also demonstrated that IL-1a or IL-1b synergizes with IL-23 to promote IL-17 production by murine T cells in the presence or absence of T cell receptor engagement (Sutton et al., 2006) . Furthermore, IL-17 production and development of EAE is compromised in IL-1 receptor type I-defective (Il1r1 À/À ) mice. IL-1 and IL-23 promote IL-17 production by memory but not naive T cells (van Beelen et al., 2007) . However, it has recently been reported that IL-1 signaling is critical for Th17 cell differentiation (Chung et al., 2009) . Moreover, our studies, together with recent reports on human Th17 cells (Manel et al., 2008; Volpe et al., 2008) and on IL-23-driven innate IL-17 production (Hue et al., 2006; Takatori et al., 2009) , suggest that the function of IL-23 may not be confined to expansion of memory Th17 cells.
Although CD4 + T cells are considered to be the major source of IL-17, especially in autoimmune diseases, recent evidence has suggested that other T cell populations can produce IL-17. Murine CD8 + T cells produce IL-17 in response to conditioned medium from dendritic cells (DCs) activated with Klebsiella pneumoniae (Happel et al., 2003) . Furthermore, unconventional T cells can also secrete IL-17 during infection (Lockhart et al., 2006; Shibata et al., 2007) . NKT cells, which express IL-23R, secrete IL-17 after stimulation with anti-CD3 and IL-23 (Rachitskaya et al., 2008) . gd T cells provide an early source of IFN-g in mucosal tissues (Lochner et al., 2008; Ivanov et al., 2006) and are pathogenic in EAE, collagen-induced arthritis (CIA), and colitis models in mice (Jensen et al., 2008; Nanno et al., 2008; Roark et al., 2007; Spahn et al., 1999) . Their pathogenic role in autoimmunity was initially thought to be mediated through IFN-g production. However, recent studies have shown that gd T cells can secrete IL-17 during infection with Mycobacterium tuberculosis (MTB) or E. coli, in which they promote neutrophil recruitment (Lockhart et al., 2006; Shibata et al., 2007) . Interestingly, it has recently been shown that IL-17 production by gd T cells is independent of IL-6 (Lochner et al., 2008) , an essential cytokine for driving the development of Th17 cells.
In this study, we address the hypothesis that gd T cells may secrete innate IL-17 in response to IL-1 and IL-23. We found that gd T cells expressed IL-23R and that stimulation with IL-1 and IL-23 promoted RORgt, IL-17A, IL-17F, IL-21, and IL-22 expression by gd T cells in the absence of T cell receptor (TCR) engagement. Furthermore, IL-17-secreting gd T cells were present at high frequency in the central nervous system (CNS) of mice with EAE, in which they functioned with CD4 + Th17 cells to mediate autoimmune pathology.
RESULTS
IL-1b and IL-23 Promote IL-17 Production by
Unconventional T Cells in the Absence of TCR Activation Consistent with previous reports on the roles of IL-6 with TGF-b and IL-1b with IL-23 in promoting IL-17 production by naive and memory T cells, respectively, we found that both of these cyto- kine combinations induced IL-17 production by murine spleen cells after stimulation with anti-CD3. In contrast, IL-6 and TGF-b failed to induce IL-17 production in the absence of TCR activation ( Figure 1A ), whereas IL-17 was produced by spleen cells stimulated with IL-23 and IL-1b in the absence of anti-CD3. Furthermore, in the presence of anti-CD3, IL-17 production in response to IL-23 and IL-1b, but also in response to IL-6 and TGF-b, was substantially reduced in spleen cells from Il1r1 À/À mice, demonstrating the critical role of IL-1 signaling in IL-17 production. IL-17 protein production was assessed after 72 hr, but was detectable at low amounts after 48 hr (Sutton et al., 2006) and was maximal in the region of 10 ng/ml of IL-1b and IL-23 (data not shown), a concentration that was used for subsequent experiments. Intracellular cytokine staining (ICS) confirmed that IL-1b and IL-23, but not IL-6 and TGF-b, induced IL-17 production by CD3 + T cells in the absence of anti-CD3 ( Figure 1B ). When activated with anti-CD3 and anti-CD28, IL-1b and IL-23 failed to stimulate IL-17 production by naive (CD4 + CD62L hi CD44 lo ) T cells but did promote IL-17 production by total CD4 + T cells ( Figure 1C ).
Furthermore, ICS demonstrated that, in the absence of anti-CD3, IL-1b and IL-23 induced IL-17 secretion by CD3 + T cells, but not by CD4 + or CD8 + T cells ( Figure 1D ). A current view on the generation of IL-17-producing T cells in vivo is that innate IL-6 and TGF-b promote development, Immunity gd T Cells Are an Important Source of Innate IL-17 whereas IL-1 and IL-23 enhance the expansion of Th17 cells, and that these innate cytokines are induced in response to pathogenassociated molecular patterns (PAMPs), including TLR and NLR agonists. Here, we examined the role of TLR and NLR-induced IL-1 and IL-23 production by DCs in promoting innate IL-17 production by T cells. Stimulation of DC with TLR and NLR agonists ( Figure 2A ) or with killed MTB ( Figure 2B ) induced high concentrations of IL-1b, IL-23, and IL-6, but interestingly no IL-12p70. Furthermore, in the absence of anti-CD3, CD3 + T cells cultured with DC that had been simulated with MTB ( Figure 2C ) or TLR and NLR agonists ( Figure S1 available online), induced IL-17 production, which was blocked by IL-1 receptor antagonist (IL-1Ra) and partially blocked by anti-IL-23R. These findings demonstrate that PAMP-activated IL-1b and IL-23 promote innate IL-17 production by T cells in the absence of TCR activation. Figure 3B ). Conversely, purified gd T cells, but not spleen cells depleted of gd T cells, secreted IL-17 in response to IL-1b and IL-23 ( Figure 3C ). ICS confirmed that a substantial proportion of gd T cells secreted IL-17 in response to IL-1b and IL-23 in the absence of anti-CD3 ( Figure 3D ). In contrast, we failed to detect IL-17 production by NK or NKT cells after stimulation of spleen cells with IL-1b and IL-23 (not shown). We next used real-time PCR to confirm the effect of IL-1b and IL-23 on expression of IL-17 and other cytokines, receptors and transcription factors associated with Th17 cells. Stimulation of purified gd T cells with IL-23 induced expression of IL-17A, IL-17F, and IL-22 mRNA, which was enhanced by addition of IL-1b, and this was significantly (p < 0.001) higher than that induced in gd T cell-depleted CD3 + T cells ( Figure 3E ). IL-21 plays a role in the development of murine CD4 + Th17 cells (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007) . We found that IL-1b and IL-23, but neither cytokine alone, promoted substantial IL-21 expression in gd T cells, but not in CD3 + T cells depleted of gd T cells ( Figure 3E ). The transcription factor RORgt is associated with the development of CD4 + Th17 cells (Ivanov et al., 2006) and is also expressed by NKT cells (Rachitskaya et al., 2008) . We demonstrate constitutive RORgt expression in gd T cells, which was enhanced by IL-23 ( Figure 3E ). It has previously been reported that IL-23R is expressed on NK cells and memory T cells (Parham et al., 2002) . We found that gd T cells expressed high constitutive levels of IL-23R, which were enhanced by stimulation with IL-23 alone or in combination with IL-1b ( Figure 3E ). Cell-surface staining and flow cytometry analysis confirmed that IL-23 promoted IL-23R expression on gd T cells ( Figure 3F ). We also examined the capacity for IL-1 and IL-23 to stimulate IL-17 production in vivo. We found substantial IL-17A and IL-17F gene expression in the draining lymph nodes 4 hr after injection of IL-1 and IL-23 into the footpad ( Figure S2A ). Consistent with a previous report (Jensen et al., 2008) , ICS revealed a relatively high frequency of IL-17-producing gd T cells in lymph nodes of naive mice. We found that this was enhanced after injection of IL-1 and IL-23 ( Figure S2B ). These findings suggest that IL-1 and IL-23 promote rapid IL-17 gene expression and protein production in vitro and in vivo and that gd T cells are a source of innate IL-17, but do not rule out other innate sources of IL-17.
IL
A High Frequency of IL-17-Secreting gd T Cells Infiltrate the CNS of Mice with EAE Having shown that gd T cells produce IL-17 in response to stimulation with IL-1b and IL-23, we examined the possibility that these cells are a source of IL-17 during development of EAE, in which IL-17 has been shown to play a key role in inflammatory pathology. We found substantial infiltration of IL-17-secreting gd T cells into the brain during the course of EAE ( Figure 4A ). gd T cells were detectable on day 7 after induction, immediately prior to onset of clinical signs of EAE, and peaked at day 10-14 and a very high proportion (50%-80%) of these cells secreted IL-17 ( Figures 4A and 4C ). In contrast, the frequency of gd T cells secreting IFN-g was significantly lower, and there was only a small increase in their numbers during the course of EAE. Conversely, the frequency of both CD4 + IFN-g + and CD4 + IL-17 + T cells was enhanced during the development of EAE ( Figure 4B ). gd T cells expressing Vg4 + are expanded in CIA (Roark et al., 2007) . We found that more than 70% of gd T cells in the brain at the acute phase of EAE were Vg4 + and that more than 50% of these secreted IL-17 ( Figure 4D ). We also detected Vg5 + cells and Vd6.3/2 + cells, but the majority of these were not IL-17
secreting. In the spleen, the overall frequency of IL-17-secreting gd T cells was lower but over 90% of these were Vg4 + ( Figure S3 ). We also found elevated IL-17 mRNA expression in the CNS during development of EAE ( Figure 4E ). In addition, IL-1b and IL-23p19 mRNA was enhanced in the spleen 1-7 days after immunization (data not shown), but was also enhanced in the CNS at the onset of clinical symptoms ( Figure 4E ), which coincided with the detection of IL-17-secreting gd T cells in the brain. These findings demonstrate that gd T cells are an important source of IL-17 in the CNS during development of EAE and, together with the data presented in Figure 3 , suggest that IL-1 and IL-23 may be an important stimulus for early production of innate IL-17 during development of EAE.
IL-17-Secreting gd T Cells Cooperate with CD4 + T Cells in the Development of EAE
We next examined the role of gd T cells in the development of the clinical symptoms of EAE. We found that EAE was less severe in Tcrd À/À mice; the onset of disease was delayed and the clinical scores were reduced ( Figure 5A ). This was associated with significantly (p < 0.01 -p < 0.001) lower MOG-specific IL-17 production by lymph nodes of Tcrd À/À mice ( Figure 5B ), suggesting that gd T cells are required for antigen-specific responses by conventional T cells during development of EAE. Furthermore, total IL-17A and IL-17F gene expression in the spleen was significantly (p < 0.05) lower in Tcrd À/À mice compared with WT mice with EAE ( Figure 5C ), suggesting that gd T cells make a major contribution to IL-17 production in vivo during development of EAE. We next examined the role of gd T cells activated by IL-1b and IL-23 in the induction of EAE. Il1r1 À/À mice were substantially more resistant to EAE than wild-type mice ( Figure 5D ). Immunity gd T Cells Are an Important Source of Innate IL-17 (Langrish et al., 2005) . We found that lymph node and spleen cells from mice with EAE stimulated with MOG in the presence of IL-1 and IL-23 induced EAE after transfer to recipient mice ( Figure 5E ). These cultured cells included IL-17-secreting gd T cells as well as CD4 + T cells, but not NK cells (data not shown).
CD4
+ and CD8 + with gd T cells purified from the cultured cells also induced mild EAE, but purified CD4 + , CD4 + and CD8 + , or gd T cells alone failed to transfer EAE ( Figures 5E and 5F ). Collectively, our data suggest that IL-17-producing gd T cells, as well as CD4 + T cells, infiltrate the CNS of mice with EAE and that both of these cell types are required for optimal development of EAE. Our findings suggest that gd T cells, as well as directly contributing to pathogenic cytokine production, may also augment IL-17 production by autoantigen-specific Th17 cells in vivo. We sought to provide further evidence for this hypothesis. Consistent with the data in Figure 3 , we found that spleen cells from Tcrd À/À mice failed to secrete IL-17 in response to IL-1b and IL-23, in the absence of anti-CD3 ( Figure 6A ). Addition of anti-CD3 (required to activate IL-17 production by Th17 cells) substantially augmented IL-17 production induced by IL-1b and IL-23 or either cytokine alone. However, this was also significantly (p < 0.001) reduced in spleen cells from Tcrd À/À mice ( Figure 6A ), suggesting that gd T cells can augment IL-17 production from ab T cells. This was confirmed by the demonstration that IL-17 production by CD4 + T cells stimulated with anti-CD3 and anti-CD28 was significantly (p < 0.001) enhanced by addition of gd T cells that had been prestimulated with IL-1b and IL-23 (and washed to remove IL-1b and IL-23), but not with gd T cells stimulated with medium only ( Figure 6B Figure S4 ). We have shown that IL-1b and IL-23 can induce IL-17 and IL-21 expression in gd T cells, and it has already been reported that IL-21 together with TGF-b or IL-23 can stimulate IL-17 production by CD4 + T cells (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007) . However, it is also possible that gd T cell-derived IL-17 may promote further IL-17 production by Th17 cells. Therefore, we examined the roles of IL-21 and IL-17 in gd T cell-induced IL-17 production by CD4 + T cells.
We found the induction of IL-17A and IL-17F mRNA expression in CD4 + T cells by supernatants from gd T cells activated with IL-1b and IL-23 was inhibited by addition of anti-IL-17 or anti-IL-21; the greatest inhibition of IL-17 expression was observed when both antibodies were added to the cultures ( Figure 6D ). These findings suggest that gd T cell-derived IL-17 and IL-21 augment IL-17 production by Th17 cells.
CD4 + T Cells and DCs Express IL-17R and Respond to IL-17
In order to provide further evidence that IL-17 may amplify its own production either by acting directly on CD4 + T cells or indirectly on DC, we examined expression of IL-17R and responsiveness of these cells to IL-17. We first showed that CD4 + T cells from naive mice express IL-17R mRNA and the expression was stronger than that observed for lung or spleen ( Figure 7A ), tissues previously shown to express IL-17R. We next used IL-17 mRNA expression to examine autocrine production of IL-17 by CD4 + T cells and found that recombinant IL-17A
induced IL-17A and IL-17F mRNA expression in CD4 + T cells ( Figure 7B ). We also examined the effect of IL-21 and found that it did not induce IL-17 or amplify IL-17-induced IL-17 expression by CD4 + T cells (not shown). However, IL-21 did enhance IL-23-induced IL-17A and IL-17F expression by CD4 + T cells ( Figure 7C ).
DCs were also found to express IL-17R, which was enhanced after stimulation with TLR agonists ( Figure 7D ). DCs secrete IL-23 after stimulation with low concentrations of IL-17 (Figure 7E) , and this was inhibited by coincubation with IL-17RFc ( Figure S5 ). Furthermore, IL-17-induced IL-23 production was enhanced by costimulation with a TLR agonist ( Figure 7F ). Moreover, LPS-induced IL-12p40, IL-1b, and IL-6 production by DC was substantially enhanced by IL-17 ( Figure 7F ). In addition, IL-17 induced TGF-b and CCL2 mRNA expression and substantially augmented LPS-induced IL-1b, IL-6, CCL2, and CXCL10 mRNA expression ( Figure 7G ). Addition of IL-17RFc reduced expression to that induced with LPS alone, confirming that the effect of IL-17 was mediated via IL-17R and not due to a contaminant in the IL-17 preparation.
We next examined an autocrine role for IL-17 in vivo by administering anti-IL-17R or IL-17 during the induction of EAE. We found a significant (p < 0.05) reduction in antigen-specific IL-17 production in lymph nodes, but not spleen, of mice treated with anti-IL-17R ( Figure S6A ). Moreover, anti-IL-17R treatment suppressed IL-17A mRNA expression in the spinal cord ( Figure S6B ). The reduction in IL-17 was associated with slower onset of EAE in these mice ( Figure S6C ). Conversely, we found that administration of IL-17 with CFA and MOG resulted in earlier onset of EAE and more pronounced clinical scores early in disease ( Figure S6D ).
These data suggest that early IL-17 has a positive rather than negative feedback role on IL-17 production, especially early in EAE. Collectively, our findings suggest that IL-1b and IL-23 promote innate IL-17 production by gd T cells, which amplifies IL-17 production by CD4 + T cells, either by interacting directly with CD4 + T cells or indirectly with DC to enhance production of innate cytokines that drive the induction and expansion of Th17 cells. Thus, gd T cells, as well as making a substantial contribution to the overall pool of IL-17 in vivo, may act as an early source of IL-17 and IL-21 to amplify Th17 cell responses.
DISCUSSION
The results of this study demonstrate that gd T cells are an important source of innate IL-17 and that these cells constitutively express IL-23R and also secrete IL-21 and IL-22. The present study also reveals a new mechanism of IL-23 and IL-1-induced IL-17 production. We demonstrate that IL-23 in combination with IL-1b promotes IL-17, IL-21, and IL-22 expression by gd T cells in the absence of additional signals. Finally, we demonstrate that gd T cells may act in an amplification loop to promote IL-17 production by Th17 cells. The transcription factor RORgt, which has been associated with the development of CD4 + Th17 cells (Ivanov et al., 2006) , is also expressed by NKT cells (Rachitskaya et al., 2008) and CD4 + CD3 À lymphoid tissue inducer (LTi)-like cells (Takatori et al., 2009) . We demonstrated constitutive expression of RORgt in gd T cells, which was enhanced by IL-23. Furthermore, IL-23 induced IL-17A, IL-17F, and IL-22 expression, which was enhanced by IL-1b. Interestingly, we found that IL-21, which is induced in naive CD4 + T cells by stimulation with anti-CD3, anti-CD28, and IL-6 or IL-6 and TGF-b (Korn et al., 2007) , was also expressed at very large amounts in gd T cells, but not by gd T cell-depleted CD3 + T cells, after stimulation with IL-1b and IL-23. In addition to the roles of IL-6 and TGF-b in promoting the differentiation of Th17 cells, there are firmly established roles for IL-23 and IL-1 in promoting IL-17 production and mediating the development of autoimmune diseases. A major function of IL-23 in autoimmunity and infection is considered to involve promoting IL-17 production from memory CD4 + T cells (Higgins et al., 2006; van Beelen et al., 2007) . However, studies in an EAE model, involving adoptive transfer of T cells into Il23a À/À mice,
showed that IL-23 played a critical role in the development but not in the effector function of encephalitogenic T cells (Thakker et al., 2007) . In an EAU model, neutralization of IL-23 reduced IL-17 production and attenuated EAU when administered immediately before and after induction of disease, but not at the effector stage of the disease Furthermore, studies in a colitis model have suggested that IL-23 can promote innate IL-17 production, but did not define the cell population involved (Hue et al., 2006) . It has also been reported that stimulation of peritoneal exudate cells with IL-23, but not by IL-6 and TGF-b, induced IL-17 production by gd T cells (Shibata et al., 2007) . Our study demonstrates a requirement for IL-1 and shows that IL-23 and IL-1b promote innate IL-17 production from gd T cells and provides an alternative mechanism whereby IL-23 and IL-1b may contribute to host defense and autoimmune inflammation. It has previously been reported that unconventional T cells, especially NKT cells, express the IL-23R and secrete IL-17 during infection or inflammation or when activated in vitro with anti-CD3 and IL-23 or with the synthetic ligand a-galactosylceramide (Lockhart et al., 2006; Rachitskaya et al., 2008; Shibata et al., 2007) . Furthermore, it has recently been demonstrated that IL-23 can promote innate IL-17 and IL-22 production by LTi-like cells when stimulated in vitro or in vivo with zymosan during infection with M. tuberculosis (Lockhart et al., 2006) . Vd1 + cells have been shown to accumulate at the site of E. coli infection, where they promote neutrophil recruitment (Shibata et al., 2007) . Moreover, there is evidence that gd T cells may have a pathogenic role in CIA (Roark et al., 2007) . Our study demonstrates that gd T cells infiltrate the CNS during the development of EAE, and a very high frequency of these cells secretes IL-17. We detected Vg4 + , Vg5 + , and Vd6.3/2 + cells, but consistent with the CIA studies (Roark et al., 2007) , the dominant IL-17-secreting gd T cells were Vg4 + . A much smaller number of gd T cells in the CNS of mice with EAE secreted IFN-g. In contrast, a similar frequency of IL-17 and IFN-g-secreting CD4 + T cells was detected in the CNS at the onset of EAE, and although the absolute numbers are greater, a lower percentage of CD4 + than gd T cells secreted IL-17. A high frequency of IL-17-secreting gd T cells has also been reported in draining lymph nodes 0-4 days after immunization with MOG and CFA, which preceded the generation of MOG-specific CD4 + T cells (Jensen et al., 2008) . Taken together with our findings, this suggests that IL-17-secreting gd T cells may play a pathogenic role early in disease and may then influence the generation of Th17 cells. Consistent with this, studies in humans have described an accumulation of gd T cells in acute MS lesions (Wucherpfennig et al., 1992) and clonal expansion of gd T cells in cerebrospinal fluid of MS patients with recent-onset disease (Shimonkevitz et al., 1993) .
Evidence that the infiltrating IL-17-secreting gd T cells may have a pathogenic function in EAE is provided by our findings, which are consistent with previous reports (Jensen et al., 2008; Spahn et al., 1999) Furthermore, this enhancement of IL-17 mRNA expression was inhibited by coculture with anti-IL-21 and anti-IL-17. Because we also found that IL-21 was expressed by gd T cells after stimulation with IL-1 and IL-23, but not either cytokine alone, these findings suggest that IL-21 may in part mediate the effect of gd T cells on IL-17 production by CD4 + T cells. This conclusion is consistent with the recent demonstration that IL-21 plays a critical role in IL-17 production by naive CD4 + T cells (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007) . The induction of IL-17A and IL-17F mRNA expression in CD4 + T cells by supernatants from gd T cells that had been stimulated with IL-1b and IL-23 was also inhibited by anti-IL-17. This was consistent with our demonstration that CD4 + T cells expressed endogenous IL-17R and responded to IL-17 by enhancing expression of IL-17A and IL-17F mRNA. However, it has been reported that IL-17-producing T cells are enhanced in the spleen or liver, but not the lymph node, of Il17ra À/À mice and that IL-17F can suppress IL-17A production by CD4 + T cells (Nagata et al., 2008; Smith et al., 2008) . We found that treatment with anti-IL-17R early in EAE reduced IL-17 production and attenuated disease, whereas administration of IL-17 with MOG and CFA enhanced the onset of EAE. Although an autocrine or paracrine role for IL-17 in modulating IL-17 production is still unclear, our findings suggest that early IL-17 has a positive rather than negative feedback role for induction of IL-17, especially early in EAE. This is consistent with our conclusions that early IL-17 from gd T cells may promote the induction or activation of Th17 cells. Our study also reveals an additional mechanism whereby IL-17-producing gd T cells may amplify Th17 responses. Addition of DCs enhanced the ability of gd T cells activated with IL-1 and IL-23 to promote IL-17 production by CD4 + T cells. hi CD44 lo T cells were purified from spleens of C57BL/6 mice with mouse T cell subset column kits (R&D). gd T cells were sorted by FACS (Dako Moflo) or MACS. Cells were cultured with IL-1b (10 ng/ml), IL-23 (10 ng/ml), TGF-b (10 ng/ml), or IL-6 (20 ng/ml), in the absence or presence of anti-CD3 (1 mg/ml) and anti-CD28 (10 mg/ml). After 24-72 hr, IL-17 concentrations in supernatants were determined by ELISA (R&D).
Dendritic Cells
Mouse bone-marrow derived immature DCs were generated as described (Higgins et al., 2006) . DCs were cultured with MTB (10-50 mg/ml; Chondrex), LPS (10-100 ng/ml; Alexis), CpG (20 mg/ml), muramyl dipeptide (20 mg/ml), peptidoglycan (25 mg/ml), or combinations thereof, with and without IL-1Ra (10 mg/ml; Anakinra) and anti-IL-23R (10 mg/ml; R&D) or with IL-17 (0.1-10 ng/ml; R&D) in the presence and absence of IL-17RFc (2 mg/ml; R&D). After 24 hr, supernatants were tested for IL-1b, IL-12p70 (R&D), IL-23 (eBiosciences), IL-6, and IL-12p40 (BD PharMingen) concentrations by ELISA.
Intracellular Cytokine Staining
Spleen cells (2 3 10 6 cells/ml) from C57BL/6 mice were incubated for 72 hr with medium or cytokines and for the last 6 hr in the presence of brefeldin A (5-10 mg/ml). Alternatively, mononuclear cells were isolated by percoll density centrifugation from the brain of mice perfused with PBS and stimulated with PMA (10 ng/ml) and ionomycin (1 mg/ml) with brefeldin A (5 mg/ml). Cells were washed and blocked with Fcg blocker (BD PharMingen; 1 mg/ml) before extracellular staining for surface CD3, gd TCR, Vg4, Vg5, Vd6.3/2, CD4, or CD8. Cells were then fixed and permeabilized (Fix and Perm Cell Permeabilization Kit; Caltag) and stained intracellularly for IL-17 or IFN-g. Flow cytometric analysis was performed with either a BD FACS Caliber and Summit software or a Cyan ADP Flow Cytometer (Dako Cytomation) with FloJo software, with gating set on isotype controls or FMOs, respectively.
Real-Time PCR gd T cells or gd-depleted T cells were purified from spleens of C57BL/6 mice and incubated for 48 hr with IL-1b (10 ng/ml), IL-23 (10 ng/ml), both, or medium alone. CD4 + T cells were stimulated with supernatants from gd T cells activated with IL-1 and IL-23, in the presence or absence of anti-IL-17 and anti-IL-21 (10 mg/ml) or with recombinant IL-17 (10 ng/ml; R&D Antigen-Specific IL-17 Production Spleen and lymph node cells (1 3 10 6 cells/ml) were stimulated with MOG (12.5, 25 and 50 mg/ml) or PMA (Sigma; 20 ng/ml) and anti-CD3 (1 mg/ml), and IL-17 concentrations in supernatants were determined by ELISA (R&D).
Statistical Analysis
Data were compared by two-tailed Student t test, Wilcoxon Rank test, and by one-way ANOVA. Where significant differences were found, the Tukey-Kramer multiple comparisons test was used for identifying differences between individual groups.
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